DaptomycinPeptide antibiotic
Daptomycin is a cyclic lipopeptide antibiotic used in serious Gram-positive bacterial infections. Its limitations are as important as its antibacterial mechanism.
What is Daptomycin?
Daptomycin is a cyclic lipopeptide antibiotic used in serious Gram-positive infections. Its clinical role includes selected bloodstream infections and endocarditis.
How it works
It interacts with bacterial membranes in a calcium-dependent manner, disrupting functions needed for survival. Lung surfactant interferes with its activity.
Effects studied
Bloodstream infection and endocarditis
A retained controlled trial compares daptomycin with standard treatment for Staphylococcus aureus bloodstream infection and endocarditis. These results do not establish usefulness for pneumonia. 1
Evidence: Controlled clinical infection study
What does the evidence show?
The archive retains a controlled study of bloodstream infection and endocarditis, plus product information. These do not support treating pneumonia with daptomycin.
A membrane-directed antibiotic
Daptomycin interacts with bacterial membranes in a calcium-dependent way, disrupting functions bacteria need to survive. Its activity against some resistant Gram-positive organisms makes it clinically important. The word “peptide” here describes chemistry, not a wellness category.
The lung exception
Lung surfactant interferes with daptomycin’s activity. Consequently, activity against an organism in laboratory testing does not by itself establish usefulness for pneumonia. A drug has to reach the infection site in an active form as well as recognise a susceptible organism.
What the clinical study adds
The retained trial compared daptomycin with standard treatment for Staphylococcus aureus bloodstream infection and endocarditis. The relevant outcomes include treatment success and complications in those settings. The findings do not establish that the medicine is superior for every resistant infection. 1
Monitoring is part of treatment
Muscle symptoms and creatine-kinase measurements matter during treatment, and kidney function affects clinical decisions. Rare serious lung reactions are also described in product information. These risks are part of the treatment decision and require specialist selection and monitoring. 2
Safety & status
Muscle symptoms, creatine-kinase measurements and kidney function need monitoring. Serious lung reactions are also described in product information. 2
Country and product status
This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.
Frequently asked questions
Why is it not used for pneumonia?
Lung surfactant interferes with antibacterial activity, so susceptibility in a laboratory does not establish effective treatment in the lung.
Why monitor muscles during treatment?
Muscle toxicity is a relevant adverse effect; clinical monitoring includes symptoms and creatine-kinase measurements. 2
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Daptomycin: paper 10.1056/NEJMoa053783 Research reference · Retained archive reference; not independently checked for this draft.
- Daptomycin: www.merck.com reference Reference or product information · Retained archive reference; not independently checked for this draft.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.